|
Motesanib Diphosphate
Description of:Motesanib Diphosphate
Motesanib Diphosphate potently inhibited VEGF-induced but not bFGF-induced proliferation of HUVECs with IC...
更多>>
|
|
|
RAF265(CHIR-265)
Description of:RAF265(CHIR-265)
RAF is a key component of the RAS/RAF/MEK/ERK signal-transduction pathway, which controls cell proliferation, d...
更多>>
|
|
|
Sunitinib Malate(SU 11248)
Description of:Sunitinib Malate(SU 11248)
Sunitinib dose-dependently inhibited stem cell factor (SCF)-induced phosphotyrosine levels on KIT (IC...
更多>>
|
|
|
PD173074
Description of:PD173074
PD173074 is a potent ATP-competitive, reversible FGFR and VEGFR inhibitor with IC50 of 5, 21.5 and ~100 nM for FGFR3, F...
更多>>
|
|
|
Regorafenib(瑞格非尼)
Description of:Regorafenib(瑞格非尼)
BAY 73-4506 is an orally bioavailable multikinase inhibitor targeting both the tumor and its vasculature.
更多>>
|
|
|
Brivanib(BMS-540215)
Description of:Brivanib(BMS-540215)
Brivanib (BMS-540215) is a VEGFR -2 inhibitor with an IC50 of 25 nM and Ki of 26 nM.
Theoret...
更多>>
|
|
|
SU-5402
Description of:SU-5402
SU 5402 inhibits tyrosine phosphorylation of VEGFR2 and PDGFR in NIH 3T3 cells with IC50 values of 0.4 and 60.9 μM, r...
更多>>
|
|
|
SU-6668(TSU-68)
Description of:SU-6668(TSU-68)
TSU-68 (SU6668)is a novel multiple receptor tyrosine kinase inhibitor with IC50 of 2.1 µM, 8 nM and 1.2 &m...
更多>>
|
|
|
AV-951(Tivozanib)
Description of:AV-951(Tivozanib)
AV-951 (Tivozanib) is a novel quinoline-urea derivative and now developed by AVEO. AV-951 also inhibits phosph...
更多>>
|
|
|
Lenvatinib(E7080)
Description of:Lenvatinib(E7080)
Lenvatinib(E7080) has been evaluated in vitro (pre-clinical) for anti-cancer effects. E7080 suppresses lymph n...
更多>>
|
|